In a study published in the prestigious journal Science, Dr. Psaila and her colleague postdoctoral researcher Lauren Murphy demonstrate that platelets serve as dynamic “sponges,” absorbing DNA fragments released into circulation from dying or dead cells. These circulating fragments, known as cfDNA, have long been understood to incite inflammatory and autoimmune reactions if accumulated unchecked. Importantly, the research reveals that platelets do not merely sequester cfDNA to prevent nonspecific inflammation; they also strategically release their DNA cargo upon activation, orchestrating precise inflammatory responses targeted to specific tissues such as injury sites.

The mechanism by which platelets interact with cfDNA may revolutionize how we understand immune surveillance and regulation. Platelets are anucleate but are pervaded by a complex internal architecture known as the open canalicular system—an intricate network of membrane-lined channels enabling the cellular uptake and release of biomolecules. This unique feature likely underpins platelets’ capability to engulf nucleic acids, including both viral genetic material and host-derived DNA fragments. The study conclusively shows that this process is active and physiologically purposeful rather than a passive residual phenomenon from their precursor cells, the megakaryocytes.

This unexpected role of platelets holds profound implications for cancer biology and diagnostics. cfDNA isolated from plasma has previously been a cornerstone for liquid biopsy assays aimed at early cancer detection and monitoring. However, current liquid biopsy protocols discard platelets during plasma preparation, inadvertently omitting a substantial reservoir that contains clinically valuable DNA, including circulating tumor DNA (ctDNA). Dr. Murphy’s analysis uncovered that platelets harbor ctDNA bearing tumor-specific mutations, even in patients exhibiting early precancerous lesions such as colonic polyps. This discovery suggests platelets may serve as a rich and underutilized source of tumor genetic information, enhancing the sensitivity and reliability of noninvasive cancer diagnostics.

Sensitivity in liquid biopsies is paramount because ctDNA is notoriously scarce during the earliest stages of oncogenesis when intervention can be most effective. By tapping into the platelet-contained DNA pool, diagnostic approaches could be drastically improved, potentially identifying malignancies far earlier than currently possible. The team’s clinical validation employed a clever biological test: platelets from pregnant women carrying male fetuses were analyzed, and fragments of the fetal Y chromosome were consistently detected, affirming that platelets actively scavenge extracellular DNA from diverse origins, including the fetus.

From a broader perspective, these findings implicate platelets as systemic biosensors, patrolling the vascular landscape to intercept genomic perturbations that signal pathological processes across tissues. This surveillance capacity complements their known roles in immune cell recruitment and pathogen neutralization. Dr. Psaila emphasizes that the ubiquity and accessibility of platelets make them ideally suited to function as circulating sentinels, capturing transient molecular signals like cfDNA that inform the physiological state of the body at large.

Future research directions will delve into the pathways through which platelets process and handle internalized DNA fragments, their mechanisms of DNA release upon activation, and the downstream immunological consequences. Understanding these processes will illuminate novel aspects of platelet biology with potential translational applications ranging from targeted immunomodulation to refined biomarker platforms.

Moreover, this work challenges long-held assumptions regarding the absence of nuclei in platelets limiting their molecular capabilities. Despite lacking genomic DNA, platelets demonstrate a sophisticated capacity to interact with extracellular nucleic acids, extending their functional repertoire. This phenomenon underscores the evolutionary ingenuity of these anucleate cells and opens a new frontier in both basic and clinical hematology.

The research was conducted with significant contributions from computational biologist Benjamin Schuster-Böckler at Ludwig Oxford, who performed data analysis to discriminate platelet-derived DNA from confounding genomic sources. Collaborative efforts between Ludwig Cancer Research, Cancer Research UK, and various funding bodies including the UK Medical Research Council, Rosetrees Trust, Kidani Memorial Trust, and Yosemite, have been instrumental in bringing this promising research to fruition.

In sum, the discovery that circulating platelets not only absorb and shield DNA fragments from provoking widespread inflammation but also carry mutational information from tumors and fetuses reshapes our understanding of their biological significance and diagnostic potential. It suggests a future in which platelet analysis becomes a routine and powerful tool in both cancer early detection and prenatal genetic screening, broadening horizons for personalized and preemptive medicine.

Subject of Research: Platelets and their role in sequestering cell-free DNA to suppress systemic inflammation and improve cancer detection.

Article Title: Platelets as Dynamic Biosensors: Unlocking Their Role in DNA Surveillance and Liquid Biopsy Sensitivity.

News Publication Date: August 15, 2025.

Web References:

• Bethan Psaila profile: https://www.ludwigcancerresearch.org/scientist/bethan-psaila/
• Original publication in Science: https://www.science.org/doi/10.1126/science.adp3971

Image Credits: Ludwig Cancer Research.

Keywords: Platelets, Cell-free DNA, Circulating tumor DNA, Cancer detection, Liquid biopsy, Inflammation, Genomics, Prenatal screening, Hematology, Immune surveillance, Molecular diagnostics, Biological sensors.

Central to their discovery is the identification of a complex reprogramming of neutrophils—white blood cells that serve as primary responders in the innate immune system—within the tumor microenvironment of bone metastases. Unlike their typical mature counterparts that aid in attacking tumors, these neutrophils are converted into an immature, immunosuppressive state. This altered functional phenotype, the researchers report in the exacting pages of Cancer Cell, severely blunts the anti-tumor immune response. The culprit behind this neutrophil reprogramming is a protein called Dickkopf-related protein 1 (DKK1), which is abundantly produced by the bone tumor niche.

DKK1, previously implicated in bone biology and cancer progression, acts as a molecular architect that remodels the cellular landscape to favor tumor persistence. Through a sophisticated series of biochemical signals, DKK1 disrupts neutrophil maturation, which consequently fosters a tumor-friendly microenvironment. This aberrant state is marked by the production of another molecule, chitinase 3-like 3 (CHI3L3), which exerts potent suppressive effects on cytotoxic CD8+ T cells—the main warriors of the adaptive immune system tasked with identifying and destroying malignant cells.

Previous research has shown neutrophils to be ambivalent players in cancer biology, with their role oscillating between tumor promotion and tumor suppression depending on their specific activation states. The Merghoub and Shi study crucially emphasizes that it is the immature, DKK1-reprogrammed neutrophils that dominate within bone metastases, effectively erecting an immunological shield that thwarts therapies designed to unleash T cell-mediated killing. This insight elucidates a pivotal reason why immune checkpoint blockade therapies, such as anti-PD-1 antibodies, fail to produce significant responses in patients whose cancers have metastasized to the bone.

In meticulously designed mouse models of triple-negative breast cancer metastatic to bone, the researchers demonstrated that blocking DKK1 with a targeted antibody markedly reversed this immune suppression. This intervention allowed neutrophils to mature appropriately, reducing CHI3L3 levels and relieving the inhibition on CD8+ T cells. Remarkably, when DKK1 blockade was combined with immune checkpoint inhibitors, tumors regressed dramatically, with some completely eradicated. These findings provide compelling preclinical evidence that DKK1-targeted therapies could synergize with existing immunotherapies to overcome resistance in bone metastases, a dire unmet clinical need.

Expanding beyond preclinical models, their analyses included patient-derived serum samples from individuals with gastric cancer and bone metastases, where elevated DKK1 levels mirrored those observed in experimental contexts. This translational aspect not only reinforces the relevance of their findings to human disease but also suggests potential biomarkers—DKK1 and CHI3L3—that could stratify patients likely to benefit from combined immunotherapeutic approaches targeting both neutrophils and T cells.

From a mechanistic standpoint, the study delved deep into the intracellular signaling pathways activated by DKK1 that orchestrate neutrophil dysfunction. By pinpointing these molecular conduits, the research identifies multiple potential pharmacological targets beyond DKK1 itself, broadening the horizon for drug development aiming to recalibrate the immune microenvironment in metastatic bone lesions.

This research further challenges the established focus on targeting adaptive immunity alone, emphasizing the critical role of innate immune cells—particularly neutrophils—in shaping therapeutic outcomes. The data argue for an integrated immunotherapeutic strategy that not only reinvigorates T cells but simultaneously reprograms neutrophils away from a suppressive phenotype, thus unleashing a coordinated immune assault on cancer.

The clinical implications are especially promising, given that DKN-01, a DKK1-blocking antibody, is already in clinical trials, accelerating the potential translation of these discoveries into effective treatments. The identification of CHI3L3 and its gene expression signatures as biomarkers opens avenues for precision medicine, enabling oncologists to tailor therapies according to the immune landscape of individual tumors.

The broader significance of this study lies in its illumination of the complex interplay between cancer cells and their microenvironment, specifically within the unique immunosuppressive context of bone metastases. By unveiling the molecular and cellular underpinnings of immunotherapy resistance, this work not only advances our understanding of cancer biology but also offers a tangible path toward improving outcomes for patients grappling with metastatic disease, for whom therapeutic options remain woefully inadequate.

In summation, this rigorous investigation by Merghoub, Shi, and colleagues delineates a novel immunosuppressive axis driven by DKK1-induced neutrophil immaturity within bone metastases. Intervening in this axis restores immune competency, sensitizes tumors to checkpoint blockade, and presents a compelling target for next-generation cancer immunotherapies. Their findings herald a paradigm shift, advocating for the co-targeting of innate and adaptive immunity in combating metastatic cancer, with a profound potential to reshape clinical practice and patient survival.

Subject of Research: Neutrophil reprogramming and immunotherapy resistance in bone metastases mediated by DKK1.

Article Title: DKK1-mediated neutrophil reprogramming fosters immunotherapy resistance in bone metastases.

News Publication Date: August 7, 2025.

Web References:

• Cancer Cell article: https://www.sciencedirect.com/science/article/abs/pii/S1535610825003137?via%3Dihub
• Related neutrophil study: https://www.nature.com/articles/s41422-025-01145-0

Image Credits: Ludwig Cancer Research, image of Taha Merghoub.

Keywords: Health and medicine, Cancer, Immunotherapy, Neutrophils, Bone metastases, DKK1, Tumor microenvironment, CD8+ T cells, Innate immunity, Immune checkpoint blockade.

One of AML’s defining features is a pervasive block in the differentiation of myeloid progenitor cells within the bone marrow. This obstruction arrests the maturation of these cells, resulting in the accumulation of immature precursors that flood the marrow and peripheral blood. This paralyses normal hematopoiesis—the vital process governing the generation and renewal of blood cells—undermining not just immune competence but a multitude of physiological functions reliant on healthy blood cell populations. Recognizing this differentiation blockade as a keystone of AML pathology has long inspired researchers to explore therapeutic avenues that could dismantle this barrier.

Led by Professor Yang Shi of Ludwig Oxford and Dr. Amir Hosseini, with pivotal contributions from Abhinav Dhall at Harvard Medical School, and collaborators at the University of Pennsylvania and University of Helsinki, the study introduces a novel combination drug therapy that tackles AML at this very checkpoint. Their work hinges on a dual mechanism designed to simultaneously activate gene expression programs that promote cellular differentiation while actively repressing those that fuel unchecked proliferation and tumorigenesis. This two-pronged approach is meticulously crafted to coax leukemic cells out of their arrested developmental state and curb their malignant growth kinetics.

Historically, the concept of differentiation therapy in AML is not new. Acute promyelocytic leukemia (APL), a distinct AML subtype, has been effectively treated with differentiation agents such as all-trans retinoic acid combined with arsenic trioxide, achieving cure rates near 95%. However, this success has been largely restricted to APL, leaving a vast majority of AML patients without analogous effective differentiation-based treatments. Addressing this unmet need, Shi and his colleagues have turned their focus to epigenetic regulators—enzymes that modulate gene expression without altering the underlying DNA sequence—specifically targeting key drivers of the differentiation blockade.

Central to the researchers’ strategy is LSD1 (lysine-specific demethylase 1), an enzyme first identified by Shi’s laboratory in 2004. LSD1 functions as an epigenetic eraser, removing methyl groups from histone proteins around which DNA is tightly coiled, thereby influencing the accessibility of genes to the cellular machinery that transcribes them. In AML cells, heightened LSD1 activity contributes to the maintenance of leukemic stem cells by reinforcing the gene expression landscape that enforces their immature, undifferentiated state. While LSD1 inhibitors have shown potential in inducing differentiation, their clinical application has been hampered by high toxicity when administered as monotherapies.

To overcome this, the study employed a systematic screen using mouse leukemic cells to identify drugs that could synergize with LSD1 inhibitors, ultimately spotlighting a clinically evaluated GSK3α/β inhibitor as a potent partner. Glycogen synthase kinase 3 (GSK3) is an enzyme known to participate in a litany of cellular processes, including WNT signaling—a pathway frequently hijacked in cancers including AML, promoting stemness and proliferation. Combining low-dose LSD1 inhibition with GSK3 blockade proved to be a potent formula for inducing differentiation and halting proliferation across multiple AML subtypes in vitro.

Subsequent in vivo experiments provided further encouragement. When administered to mice engrafted with human AML cells, the combination therapy not only promoted leukemic cell maturation and suppressed their division but also extended the survival of these animal models. Intriguingly, the therapeutic effects appeared to selectively target leukemic cells without adversely affecting normal hematopoietic stem cells, suggesting a favorable therapeutic index that could translate into lower toxicity profiles for patients.

The molecular analyses underpinning these findings revealed that the drug combination reprograms gene expression networks by suppressing the stemness signature that confers malignancy, while promoting differentiation pathways. This molecular rewiring mitigates the pathological overactivation of the WNT signaling cascade—an insight that may have far-reaching implications beyond AML, potentially informing treatment strategies for other malignancies marked by similar pathway dysregulations.

Moreover, gene-expression profiling of AML patients demonstrated that the therapeutic signature induced by the drug combo aligns with the expression landscape observed in individuals exhibiting prolonged survival. This correlation underscores the potential real-world relevance of the preclinical findings and bolsters the rationale for advancing this treatment regimen into clinical trials. Both LSD1 and GSK3α/β inhibitors are already under clinical evaluation for other indications, smoothing the pathway for translational research and swift clinical implementation.

The team’s holistic approach blends innovative epigenetic modulation with an existing pharmacological arsenal to surmount a longstanding hurdle in AML therapy. By dismantling the differentiation blockade, their combination therapy holds promise not only for extending survival but also for improving the quality of life in AML patients, who often endure toxic and debilitating treatments. The prospect of converting a lethal, rapidly progressing cancer into a manageable or even curable disease marks a new frontier in oncology.

Looking ahead, the investigators are poised to translate these promising preclinical results into human clinical trials, where safety and efficacy will be rigorously tested. Their work exemplifies the power of integrative science—melding molecular biology, pharmacology, and clinical insight—to produce breakthrough therapies. If successful, this approach could redefine AML treatment standards and inspire analogous strategies against other epigenetically driven cancers.

This landmark study was made possible through generous support from Ludwig Cancer Research, the U.S. National Institutes of Health, the Research Council of Finland, Cancer Foundation Finland, the Sigrid Jusélius Foundation, the National Institute for Health Research, the Oxford Biomedical Research Centre, and Cancer Research UK. Harnessing the synergy of international expertise and funding, it represents a collective stride forward in the global battle against cancer.

In addition to his leadership role at Ludwig Oxford, Yang Shi serves as a Professor in the Nuffield Department of Medicine at the University of Oxford, further underscoring the study’s strong academic foundation. The collaborative, interdisciplinary nature of this research embodies the future of cancer therapeutics, where innovative ideas swiftly transition from bench to bedside, offering renewed hope to patients facing devastating diagnoses.

Subject of Research: Therapeutic strategies targeting differentiation blockade in acute myelogenous leukemia (AML)

Article Title: Not provided

News Publication Date: April 16, 2025

Web References:
https://www.nature.com/articles/s41586-025-08915-1

References: Information not explicitly provided beyond the publication in Nature.

Image Credits: Not provided

Keywords: Health and medicine, Cancer research, Cancer, Genomics